Yongyin Li, Weibin Wang, Libo Tang, Xuanqiu He, Xin Yan, Xiaoyong Zhang, Youfu Zhu, Jian Sun, Yongquan Shi, Xiong Ma, Ian R. Mackay, M. Eric Gershwin, Ying Han, Jinlin Hou – 27 January 2015 – The serological hallmark of primary biliary cirrhosis (PBC) is the presence of high titer and specific antimitochondrial antibodies (AMAs). Although there is no global immune defect in patients with PBC, there is widespread dysregulated B‐cell function, including increased sera levels of immunoglobulin M and enhanced B‐cell responses to cytosine‐phosphate‐guanine stimulation.

Jeong Won Jang, Jong Young Choi, Young Seok Kim, Hyun Young Woo, Sung Kyu Choi, Chang Hyeong Lee, Tae Yeob Kim, Joo Hyun Sohn, Won Young Tak, Kwang‐Hyub Han – 27 January 2015 – The effect of viral suppression on long‐term disease outcome after decompensation in patients with hepatitis B virus (HBV)‐related cirrhosis has not been established. The aim of this study was to determine the long‐term effect of antiviral therapy (AVT) in patients with HBV‐related decompensated cirrhosis.

David R. Nelson, James N. Cooper, Jacob P. Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley F. Freilich, Ziad H. Younes, William Harlan, Reem Ghalib, Godson Oguchi, Paul J. Thuluvath, Grisell Ortiz‐Lasanta, Mordechai Rabinovitz, David Bernstein, Michael Bennett, Trevor Hawkins, Natarajan Ravendhran, Aasim M. Sheikh, Peter Varunok, Kris V. Kowdley, Delphine Hennicken, Fiona McPhee, Khurram Rana, Eric A.

David R. Nelson, James N. Cooper, Jacob P. Lalezari, Eric Lawitz, Paul J. Pockros, Norman Gitlin, Bradley F. Freilich, Ziad H. Younes, William Harlan, Reem Ghalib, Godson Oguchi, Paul J. Thuluvath, Grisell Ortiz‐Lasanta, Mordechai Rabinovitz, David Bernstein, Michael Bennett, Trevor Hawkins, Natarajan Ravendhran, Aasim M. Sheikh, Peter Varunok, Kris V. Kowdley, Delphine Hennicken, Fiona McPhee, Khurram Rana, Eric A.

Peipei Lu, Jiong Yan, Ke Liu, Wojciech G. Garbacz, Pengcheng Wang, Meishu Xu, Xiaochao Ma, Wen Xie – 22 January 2015 – The aryl hydrocarbon receptor (AHR), also known as the dioxin receptor, was originally characterized as a xenobiotic receptor that senses xenotoxicants. We investigated the endobiotic and hepatic role of AHR in fatty liver and energy metabolism and identified the endocrine factor that mediates the metabolic function of AHR.

Glen Lutchman, W. Ray Kim – 22 January 2015

Michele Barone, Antonella Notarnicola, Giuseppe Lopalco, Maria Teresa Viggiani, Francesco Sebastiani, Michele Covelli, Florenzo Iannone, Alfonso W. Avolio, Alfredo Di Leo, Luca Cantarini, Giovanni Lapadula – 22 January 2015 – European and Asian studies report conflicting data on the risk of hepatitis B virus (HBV) reactivation in rheumatologic patients with a previously resolved HBV (prHBV) infection undergoing long‐term biologic therapies. In this patient category, the safety of different immunosuppressive biologic therapies, including rituximab, was assessed.

Cynthia Tsien, Gangarao Davuluri, Dharmvir Singh, Allawy Allawy, Gabriella A.M. Ten Have, Samjhana Thapaliya, John M. Schulze, David Barnes, Arthur J. McCullough, Marielle P.K.J. Engelen, Nicolaas E.P. Deutz, Srinivasan Dasarathy – 22 January 2015 – Skeletal muscle loss (sarcopenia) is a major clinical complication in alcoholic cirrhosis with no effective therapy. Skeletal muscle autophagic proteolysis and myostatin expression (inhibitor of protein synthesis) are increased in cirrhosis and believed to contribute to anabolic resistance.

Michael L. Volk – 20 January 2015 – Watch a video presentation of this article

Jennifer C. Price, Norah A. Terrault – 20 January 2015 – Although chronic infection with hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States, graft and patient survival rates are reduced because of HCV recurrence after transplant. Interferon‐based antiviral treatment administered either before or after transplant to prevent or treat HCV recurrence, respectively, is limited because of poor tolerability and low efficacy.